Paul J Keall1, Emma Colvill2, Ricky O'Brien1, Jin Aun Ng1, Per Rugaard Poulsen3, Thomas Eade4, Andrew Kneebone4, Jeremy T Booth4. 1. Radiation Physics Laboratory, Sydney Medical School, University of Sydney, NSW 2006, Australia. 2. Radiation Physics Laboratory, Sydney Medical School, University of Sydney, NSW 2006, Australia and Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW 2065, Australia. 3. Department of Oncology, Aarhus University Hospital, Aarhus 8000, Denmark and Institute of Clinical Medicine, Aarhus University, Aarhus 8000, Denmark. 4. Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW 2065, Australia.
Abstract
PURPOSE: We report on the clinical process, quality assurance, and geometric and dosimetric results of the first clinical implementation of electromagnetic transponder-guided MLC tracking which occurred on 28 November 2013 at the Northern Sydney Cancer Centre. METHODS: An electromagnetic transponder-based positioning system (Calypso) was modified to send the target position output to in-house-developed MLC tracking code, which adjusts the leaf positions to optimally align the treatment beam with the real-time target position. Clinical process and quality assurance procedures were developed and performed. The first clinical implementation of electromagnetic transponder-guided MLC tracking was for a prostate cancer patient being treated with dual-arc VMAT (RapidArc). For the first fraction of the first patient treatment of electromagnetic transponder-guided MLC tracking we recorded the in-room time and transponder positions, and performed dose reconstruction to estimate the delivered dose and also the dose received had MLC tracking not been used. RESULTS: The total in-room time was 21 min with 2 min of beam delivery. No additional time was needed for MLC tracking and there were no beam holds. The average prostate position from the initial setup was 1.2 mm, mostly an anterior shift. Dose reconstruction analysis of the delivered dose with MLC tracking showed similar isodose and target dose volume histograms to the planned treatment and a 4.6% increase in the fractional rectal V60. Dose reconstruction without motion compensation showed a 30% increase in the fractional rectal V60 from that planned, even for the small motion. CONCLUSIONS: The real-time beam-target correction method, electromagnetic transponder-guided MLC tracking, has been translated to the clinic. This achievement represents a milestone in improving geometric and dosimetric accuracy, and by inference treatment outcomes, in cancer radiotherapy.
PURPOSE: We report on the clinical process, quality assurance, and geometric and dosimetric results of the first clinical implementation of electromagnetic transponder-guided MLC tracking which occurred on 28 November 2013 at the Northern Sydney Cancer Centre. METHODS: An electromagnetic transponder-based positioning system (Calypso) was modified to send the target position output to in-house-developed MLC tracking code, which adjusts the leaf positions to optimally align the treatment beam with the real-time target position. Clinical process and quality assurance procedures were developed and performed. The first clinical implementation of electromagnetic transponder-guided MLC tracking was for a prostate cancerpatient being treated with dual-arc VMAT (RapidArc). For the first fraction of the first patient treatment of electromagnetic transponder-guided MLC tracking we recorded the in-room time and transponder positions, and performed dose reconstruction to estimate the delivered dose and also the dose received had MLC tracking not been used. RESULTS: The total in-room time was 21 min with 2 min of beam delivery. No additional time was needed for MLC tracking and there were no beam holds. The average prostate position from the initial setup was 1.2 mm, mostly an anterior shift. Dose reconstruction analysis of the delivered dose with MLC tracking showed similar isodose and target dose volume histograms to the planned treatment and a 4.6% increase in the fractional rectal V60. Dose reconstruction without motion compensation showed a 30% increase in the fractional rectal V60 from that planned, even for the small motion. CONCLUSIONS: The real-time beam-target correction method, electromagnetic transponder-guided MLC tracking, has been translated to the clinic. This achievement represents a milestone in improving geometric and dosimetric accuracy, and by inference treatment outcomes, in cancer radiotherapy.
Authors: Ryan L Smith; Amit Sawant; Lakshmi Santanam; Raghu B Venkat; Laurence J Newell; Byung-Chul Cho; Per Poulsen; Herbert Catell; Paul J Keall; Parag J Parikh Journal: Int J Radiat Oncol Biol Phys Date: 2009-04-23 Impact factor: 7.038
Authors: Amit Sawant; Ryan L Smith; Raghu B Venkat; Lakshmi Santanam; Byungchul Cho; Per Poulsen; Herbert Cattell; Laurence J Newell; Parag Parikh; Paul J Keall Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-26 Impact factor: 7.038
Authors: Per R Poulsen; Jesper Carl; Jane Nielsen; Martin S Nielsen; Jakob B Thomsen; Henrik K Jensen; Benedict Kjærgaard; Peter R Zepernick; Esben Worm; Walther Fledelius; Byungchul Cho; Amit Sawant; Dan Ruan; Paul J Keall Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-24 Impact factor: 7.038
Authors: Paul J Keall; Amit Sawant; Byungchul Cho; Dan Ruan; Junqing Wu; Per Poulsen; Jay Petersen; Laurence J Newell; Herbert Cattell; Stine Korreman Journal: Int J Radiat Oncol Biol Phys Date: 2010-07-07 Impact factor: 7.038
Authors: Jeff M Michalski; Hiram Gay; Andrew Jackson; Susan L Tucker; Joseph O Deasy Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Amit Sawant; Raghu Venkat; Vikram Srivastava; David Carlson; Sergey Povzner; Herb Cattell; Paul Keall Journal: Med Phys Date: 2008-05 Impact factor: 4.071
Authors: Vincent Caillet; Ricky O'Brien; Douglas Moore; Per Poulsen; Tobias Pommer; Emma Colvill; Amit Sawant; Jeremy Booth; Paul Keall Journal: Med Phys Date: 2019-03-04 Impact factor: 4.071
Authors: S R Bowen; M J Nyflot; C Herrmann; C M Groh; J Meyer; S D Wollenweber; C W Stearns; P E Kinahan; G A Sandison Journal: Phys Med Biol Date: 2015-04-17 Impact factor: 3.609